Drug Profile
AD 639
Alternative Names: AD639Latest Information Update: 14 Jul 2020
Price :
$50
*
At a glance
- Originator Apnimed
- Developer Apnimed; The Turner Institute for Brain and Mental Health
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Sleep apnoea syndrome